Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 3/20 | 0.43 |
| ▸ | WEE1 | P30291 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 4/20 | 0.41 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.39 |
| ▸ | CCNK | O75909 | 3/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.39 |
| ▸ | CDK2 | P24941 | 3/20 | 0.39 |
| ▸ | CDK9 | P50750 | 3/20 | 0.39 |
| ▸ | CDK12 | Q9NYV4 | 3/20 | 0.39 |
| ▸ | CDK7 | P50613 | 1/20 | 0.38 |
| ▸ | CCNH | P51946 | 1/20 | 0.38 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10246428 | 0.93 | WEE1 (0.44) | PTK2WEE1FLT3TNK2CHEK1 | |
| SCHEMBL10246368 | 0.84 | CDK4 (0.47) | PTK2FLT3CHEK1CCNT1CCNK | |
| SCHEMBL14866053 | 0.82 | WEE1 (0.43) | PTK2WEE1TNK2CHEK1 | |
| SCHEMBL13553894 | 0.82 | WEE1 (0.53) | PTK2WEE1FLT3TNK2CCNT1 | |
| SCHEMBL14681973 | 0.82 | STK4 (0.46) | WEE1TNK2 | |
| SCHEMBL15787969 | 0.80 | STK4 (0.44) | WEE1TNK2 | |
| SCHEMBL15035089 | 0.80 | STK4 (0.44) | WEE1TNK2CCNT1CCNKCCNE1 | |
| SCHEMBL13553614 | 0.80 | SIK2 (0.44) | TNK2CCNT1CCNKCCNE1CDK2 | |
| SCHEMBL13553730 | 0.80 | TNK2 (0.45) | PTK2WEE1TNK2 | |
| SCHEMBL15041489 | 0.79 | STK4 (0.43) | WEE1TNK2CCNT1CCNKCCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS HOLDINGS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | PAK2, PAK1, PAK6 | PTK2 61/4885WEE1 368/4885FLT3 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.